Answers are grounded in this paper and cite their sources.
Phase I/II trial shows stavudine improves disease activity in children with HIV, indicating its potential as an antiretroviral drug.
This study shows stavudine (d4T) to be well-absorbed in children, with plasma levels obtained comparable to those believed therapeutic in adults, and with CSF penetration similar to that seen with zidovudine. The dose-limiting peripheral neuropathy seen in adults was not observed in the study. No other dose-related clinical or laboratory adverse effects were observed; dose-limiting laboratory abnormalities did occur in children with preexisting abnormal values. Comments on efficacy are limited due to the small sample size and short duration of this Phase I/II study. However, preliminary data suggested improvement in both clinical and laboratory markers of disease activity. Stavudine appears likely to be a useful antiretroviral drug for use in treating children with HIV infection; further studies of efficacy are underway.
No takes yet. Share an insight, caveat, or question.
Sinclair et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: